For the Inventor, By the Inventor

Enter assignee name

New Haven, CT, United States of America

Curagen Corporation

USPTO Granted Patents = 84

% Expired Patents = 32.1

CIPO Patents = 1

EPO Patents = 4

Forward Citations = 2,352

Loading Chart...

Loading Chart...

122 inventors (with patents filed for the assignee):

Jonathan Marc Rothberg (23 out of 403 patents)

Richard August Shimkets (21 out of 24 patents)

John W Simpson (16 out of 30 patents)

4. Michael W Deem (12 out of 13 patents)

5. Krishnan Nandabalan (11 out of 18 patents)

6. Meijia Yang (11 out of 11 patents)

7. Gregory T Went (10 out of 10 patents)

8. Luca Rastelli (8 out of 16 patents)

9. Catherine Burgess (7 out of 8 patents)

10. Michael Jeffers (6 out of 8 patents)

11. Ferenc L Boldog (6 out of 10 patents)

12. Sudhirdas K Prayaga (6 out of 6 patents)

13. Muralidhara Padigaru (6 out of 7 patents)

14. Kimberly Spytek (6 out of 8 patents)

15. John R MacDougall (6 out of 8 patents)

Core Competencies:

Antibodies

Polypeptides

Nucleic Acids

Cytokines

FGF Proteins

Gene Expression

Biological Macromolecules

Inflammatory Bowel Disease

Cancer Diagnostics

Stroke

Therapeutic Proteins

Cardiac Hypertrophy

84 patents: Sort by Forward Citations

1. 8067544 - Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof (2011-11-29),

2. 7566536 - WNT-regulated cytokine-like polypeptide and nucleic acids encoding same (2009-07-28),

3. 7291483 - FGF-CX polynucleotide sequences and methods of producing same (2007-11-06),

4. 7276593 - Proteins and nucleic acids encoding same (2007-10-02),

5. 7259144 - Methods for diagnosing and treatment of hyperphosphatemic conditions using FGF20 polypeptides (2007-08-21),

6. 7253266 - Polypeptides of FGF-CX (2007-08-07),

7. 7189693 - Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides (2007-03-13),

8. 7122345 - Nucleic acid encoding a NOVX13 polypeptide (2006-10-17),

9. 7112668 - Polypeptides and nucleic acids encoded thereby (2006-09-26),

10. 7109000 - Proteins and nucleic acids encoding same (2006-09-19),

11. 7108972 - Proteins, polynucleotides encoding them and methods of using the same (2006-09-19),

12. 7060444 - Zone 3 necrosis associated markers and method of use thereof (2006-06-13),

13. 7056885 - Fibroblast growth factor and nucleic acids encoding same (2006-06-06),

14. 7045509 - Proteins and nucleic acids encoding same (2006-05-16),

15. 7033790 - Proteins and nucleic acids encoding same (2006-04-25),

CuraGen Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative cancer therapies. With a strong emphasis on personalized medicine, CuraGen leverages its expertise in genomics and drug development to target specific genetic markers associated with different types of cancer. Through strategic partnerships and collaborations, the company aims to bring novel treatments to patients in need, ultimately improving outcomes and quality of life. For more information, please visit the CuraGen website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Curagen Corporation

84 Patents

#5 in New Haven, CT

#122 in Connecticut

#4,423 in US

#9,044 in the World

New Haven, CT, United States of America

Curagen Corporation

Forward Citations = 2,352

122 inventors:

Jonathan Marc Rothberg (23 out of 403 patents)

Richard August Shimkets (21 out of 24 patents)

John W Simpson (16 out of 30 patents)

4. Michael W Deem (12 out of 13 patents)

5. Krishnan Nandabalan (11 out of 18 patents)

Please report any incorrect information to [email protected]

Loading…